Eupraxia Pharmaceuticals Inc
TSX:EPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eupraxia Pharmaceuticals Inc
Depreciation & Amortization
Eupraxia Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Depreciation & Amortization
-CA$164.4k
|
CAGR 3-Years
5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Depreciation & Amortization
-CA$76.9k
|
CAGR 3-Years
-134%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Depreciation & Amortization
-CA$178k
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
0%
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eupraxia Pharmaceuticals Inc
Glance View
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. The company is headquartered in Victoria, British Columbia. The company went IPO on 2021-03-09. The firm's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The firm's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The firm is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The firm is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
See Also
What is Eupraxia Pharmaceuticals Inc's Depreciation & Amortization?
Depreciation & Amortization
-164.4k
CAD
Based on the financial report for Dec 31, 2025, Eupraxia Pharmaceuticals Inc's Depreciation & Amortization amounts to -164.4k CAD.
What is Eupraxia Pharmaceuticals Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-6%
Over the last year, the Depreciation & Amortization growth was -44%. The average annual Depreciation & Amortization growth rates for Eupraxia Pharmaceuticals Inc have been 5% over the past three years , -6% over the past five years .
